Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Cash from Investing Activities (2021 - 2025)

Historic Cash from Investing Activities for ARS Pharmaceuticals (SPRY) over the last 5 years, with Q3 2025 value amounting to -$45.0 million.

  • ARS Pharmaceuticals' Cash from Investing Activities fell 36745.75% to -$45.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$69.1 million, marking a year-over-year decrease of 41849.02%. This contributed to the annual value of -$106.1 million for FY2024, which is 2170.34% down from last year.
  • Latest data reveals that ARS Pharmaceuticals reported Cash from Investing Activities of -$45.0 million as of Q3 2025, which was down 36745.75% from $48.6 million recorded in Q2 2025.
  • ARS Pharmaceuticals' 5-year Cash from Investing Activities high stood at $48.6 million for Q2 2025, and its period low was -$111.5 million during Q1 2023.
  • Over the past 5 years, ARS Pharmaceuticals' median Cash from Investing Activities value was -$35000.0 (recorded in 2021), while the average stood at -$8.5 million.
  • Data for ARS Pharmaceuticals' Cash from Investing Activities shows a peak YoY increase of 20450909.09% (in 2023) and a maximum YoY decrease of 53107142.86% (in 2023) over the last 5 years.
  • ARS Pharmaceuticals' Cash from Investing Activities (Quarter) stood at $40.7 million in 2021, then plummeted by 100.31% to -$126000.0 in 2022, then soared by 20765.87% to $26.0 million in 2023, then tumbled by 490.8% to -$101.8 million in 2024, then soared by 55.8% to -$45.0 million in 2025.
  • Its Cash from Investing Activities stands at -$45.0 million for Q3 2025, versus $48.6 million for Q2 2025 and $29.1 million for Q1 2025.